• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Arbutus Biopharma Corp (ABUS)

Common Shares
Sell: $2.64|Buy: $2.73|Change: 0.03 (1.12%)

Open 

$2.71

Previous close 

$2.68

Trade high 

$2.85

Volume 

683,613

Year high 

$3.29

Year low 

$1.69

Dividend yield 

-

Market capitalisation 

$488.27 mn

P/E ratio 

-

ISIN 

CA03879J1003

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 03/05/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Arbutus Biopharma Corp+ 1.12
More...

Company profile

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.